Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers
Meinusha Govindarajan,Salvador Mejia-Guerrero,Shawn C Chafe,Shahbaz Khan,Wei Shi,Matthew Waas,Amanda Khoo,Lydia Y Liu,Vladimir Ignatchenko,Simona Principe,Lusia Sepiashvili,Nazanin Tatari,Chitra Venugopal,Petar Miletic,Max Topley,Shan Grewal,Dillon McKenna,Maria-Jose Sandi,Nhu-An Pham,Alison Casey,Hyeyeon Kim,Christina Karamboulas,Jalna Meens,Peter Bergqvist,Begonia Silva,Patrick Chan,Liza Cerna-Portillo,Jasmine Chin,Abilasha Rao-Bhatia,Ming-Sound Tsao,Rama Khokha,Susie Su,Wei Xu,David Goldstein,Laurie Ailles,Vuk Stambolic,Fei-Fei Liu,Emma Cummins,Ismael Samudio,Sheila K Singh,Thomas Kislinger
DOI: https://doi.org/10.1101/2024.12.11.627962
2024-12-14
Abstract:Cell surface proteins offer significant cancer therapeutic potential attributable to their accessible membrane localization and central role in cellular signaling. Despite this, their promise remains largely untapped due to the technical challenges inherent to profiling cell surface proteins. Here, we employed N-glycoproteomics to analyze 85 patient-derived xenografts (PDX), constructing Glyco PDXplorer - an in vivo pan-cancer atlas of cancer-derived cell surface proteins. We developed a target discovery pipeline to prioritize proteins with favorable expression profiles for immunotherapeutic targeting and validated FAT2 as a head and neck squamous cancer (HNSC) enriched surface protein with limited expression in normal tissue. Functional studies revealed that FAT2 is essential for HNSC growth and adhesion through regulation of surface architecture and integrin-PI3K signaling. Chimeric antigen receptor (CAR) T cells targeting FAT2 demonstrated potent anti-tumor activity in HNSC models. This work lays the foundation for developing FAT2-targeted therapies and represents a pivotal resource to inform therapeutic target discovery for multiple cancers.
Cancer Biology